Olema Pharmaceuticals, Inc. (OLMA) News
Follow Olema Pharmaceuticals, Inc. (OLMA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Olema Pharmaceuticals Q3'26 Earnings Preview
Olema Pharmaceuticals is scheduled to report Q3'26 results on November 10. Revenue is estimated at 0 USD and EPS at (0.64) USD.
EQUITY | Nov 03, 2026, 12:01 PM UTC
L
Olema drops after hours on AstraZeneca Etcamah data
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 11, 2026, 10:33 PM UTC
L
Olema Oncology reports inducement grants under Nasdaq Rule 5635(c)(4)
Olema Oncology disclosed inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:30 PM UTC
L
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
EQUITY | Aug 31, 2026, 08:38 PM UTC
L
OLMA - Olema Oncology to Participate in Upcoming Investor Conferences
OLMA - Olema Oncology to Participate in Upcoming Investor Conferences
EQUITY | Aug 31, 2026, 08:30 PM UTC
L
OLMA Previewing SERENA-4 in 2H and its impact @ Piper
OLMA Previewing SERENA-4 in 2H and its impact @ Piper
EQUITY | Aug 20, 2026, 12:04 PM UTC
L
Olema Oncology appoints Jason O’Byrne as Chief Financial Officer
Olema Oncology appoints Jason O’Byrne as Chief Financial Officer, according to TradeXchange Newsdesk.
EQUITY | Aug 13, 2026, 11:01 AM UTC
L
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ: OLMA ) with a Buy and lowers the price target from $62 to $59.
EQUITY | Aug 11, 2026, 07:28 PM UTC
L
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals Inc. (NASDAQ: OLMA ) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027. Addi
EARNINGS | Aug 11, 2026, 06:27 PM UTC
L
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of OppFi Inc (NYSE: OPFI ) fell sharply in pre-market trading after the company reported worse-than-expected
EARNINGS | Aug 11, 2026, 12:04 PM UTC